JPRN-UMIN000040275已完成未知
The efficacy and safety of FOLFOXIRI for unresectable advanced rectal cancer : a prospective observational study - The efficacy and safety of FOLFOXIRI for unresectable advanced rectal cancer : a prospective observational study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. 2.Active infections, including HBs antigen positive 3.Body temperature >= 38 degrees Celsius 4.Serious complications 5.Currently treated with systemic steroids or immunosuppressive agents 6.Not appropriate for the trial by other reasons
研究者
相似试验
已完成
不适用
Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting.Borderline resectable pancreatic cancerJPRN-UMIN000034509Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Center, Saitama Medical University30
已完成
不适用
Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancerunresectable and recurrence pancreatic cancerJPRN-UMIN000014658Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)329
已完成
2 期
A Multicenter, Clinical Phase II study of FOLFOXIRI with Bevacizumab As First-line Therapy in Patients with Metastatic Colorectal Cancer.Patients with metastatic colorectal cancer.JPRN-UMIN000013797EPS Corporation65
进行中（未招募）
1 期
A study of a drug (Ferriprox®) that removes extra iron from the body, to see how safe it is and how well it works in patients with sickle cell disease.Iron overload in sickle cell disease or other anemiasMedDRA version: 20.0 Level: SOC Classification code 10005329 Term: Blood and lymphatic system disorders System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-005685-30-GBApoPharma Inc.300
已完成
2 期
The feasibility and efficacy of neoadjuvant FOLFOXIRI followed by laparoscopic surgery for locally advaned rectal cancer: A phase II studycolorectal cancerJPRN-UMIN000026575Osaka Medical College Hospital58